Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 18/20 | 0.56 |
| ▸ | FABP3 | P05413 | 1/20 | 0.49 |
| ▸ | FABP4 | P15090 | 1/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5098308 | 0.92 | GCGR (0.50) | GCGRFABP3FABP4FABP5DPP4 | |
| SCHEMBL27293870 | 0.91 | GCGR (0.49) | GCGRFABP3FABP4FABP5DPP4 | |
| SCHEMBL9870958 | 0.90 | GCGR (0.72) | GCGRFABP3FABP4FABP5DPP4 | |
| SCHEMBL9870499 | 0.86 | GCGR (0.47) | GCGRFABP3FABP4FABP5DPP4 | |
| SCHEMBL8876019 | 0.84 | FABP3 (0.51) | GCGRFABP3FABP4FABP5 | |
| SCHEMBL8875946 | 0.84 | FABP3 (0.60) | GCGRFABP3FABP4FABP5 | |
| SCHEMBL8949663 | 0.84 | GCGR (0.61) | GCGRFABP3FABP4FABP5DPP4 | |
| SCHEMBL8879687 | 0.83 | FABP3 (0.50) | GCGRFABP3FABP4FABP5 | |
| SCHEMBL6565362 | 0.83 | GCGR (0.79) | GCGR | |
| SCHEMBL5098490 | 0.83 | GCGR (0.46) | GCGRFABP3FABP4FABP5DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6218431-B1 | GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES | BAYER CORPORATION | 2001-04-17 | — | — | US | disclosed |
| CN-1274719-A | Process for preparation of substituted pyridine compound | BAYER AG (DE) | 2000-11-29 | — | — | CN | disclosed |
| CN-1055684-C | Process for preparing substituted pyridine compounds | BAYER AG (DE) | 2000-08-23 | — | — | CN | disclosed |
| EP-0934274-A1 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | Bayer Corporation (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998004528-A2 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | BAYER CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |